Main navigation

Products we regulate
Product safety
How we regulate
Guidance and resources

Mundipharma Pty Ltd

Regulatory activities for this sponsor.

- LinkedIn
- (Twitter)
- Facebook
- Email

Loading...

Type

Cancellation by sponsor (114)
ARTG (99)
Australian Public Assessment Report (AusPAR) (9)
Prescription medicine registration (2)
Cancellation or suspension (1)

Date

2024 (16)
2023 (1)
2022 (62)
2021 (3)
2020 (28)
2019 (5)
2018 (7)
2017 (19)
2016 (11)
2015 (8)
2014 (8)
2013 (14)
2012 (1)
2011 (2)
2010 (7)
2005 (6)
2003 (3)
2001 (3)
2000 (7)
1999 (4)
1996 (1)
1995 (3)
1994 (1)
1993 (3)
1991 (2)

Results for "[search-keyword]"

Search

Sponsor content

225 result(s) found, displaying 151 to 160

OXYCONTIN oxycodone hydrochloride 15mg modified release tablet bottle Cancelled under s30(1)(c)

30 June 2017

Cancellation by sponsor

Requested by Mundipharma Pty Ltd
OXYCONTIN oxycodone hydrochloride 30mg modified release tablet bottle Cancelled under s30(1)(c)

30 June 2017

Cancellation by sponsor

Requested by Mundipharma Pty Ltd
OXYCONTIN oxycodone hydrochloride 60mg modified release tablet bottle Cancelled under s30(1)(c)

30 June 2017

Cancellation by sponsor

Requested by Mundipharma Pty Ltd
OXYCONTIN oxycodone hydrochloride 80mg modified release tablet bottle Cancelled under s30(1)(c)

30 June 2017

Cancellation by sponsor

Requested by Mundipharma Pty Ltd
OXYCONTIN oxycodone hydrochloride 20mg modified release tablet bottle Cancelled under s30(1)(c)

30 June 2017

Cancellation by sponsor

Requested by Mundipharma Pty Ltd
OXYCONTIN oxycodone hydrochloride 40mg modified release tablet bottle Cancelled under s30(1)(c)

30 June 2017

Cancellation by sponsor

Requested by Mundipharma Pty Ltd
OXYCONTIN oxycodone hydrochloride 10mg modified release tablet bottle Cancelled under s30(1)(c)

30 June 2017

Cancellation by sponsor

Requested by Mundipharma Pty Ltd
AusPAR: Oxycodone / Naloxone

7 June 2017

Australian Public Assessment Report (AusPAR)

Australian Public Assessment Report for Oxycodone / Naloxone
DILAUDID-HP hydromorphone hydrochloride 500mg/50mL injection vial Cancelled under s30(1)(c)

2 March 2017

Cancellation by sponsor

Requested by Mundipharma Pty Ltd
DILAUDID-HP hydromorphone hydrochloride 500mg/50mL injection vial Cancelled under s30(1)(c) of the Act

2 March 2017

Cancellation by sponsor

Requested by Mundipharma Pty Ltd

Pages

First page
Previous page
…
Page 12
Page 13
Page 14
Page 15
Current page 16
Page 17
Page 18
Page 19
Page 20
…
Next page
Last page

Is there anything wrong with this page?

Help us improve the Therapeutic Goods Administration site

What were you doing? (mandatory)

What went wrong? (mandatory)

Leave this field blank

Using our website

Accessibility
Privacy
Disclaimer
Copyright
Freedom of information

Quick links

Search our databases
Report a problem or side effect
TGA Business Services
Special Access Scheme
Authorised Prescriber
Office of Drug Control
State and territory contacts

Connect with us

Subscribe to updates
Contact us
Facebook
(Twitter)
Youtube
Instagram
LinkedIn

Help us improve

We are always looking for ways to improve our website.

Provide feedback

The Department of Health and Aged Care acknowledges First Nations peoples as the Traditional Owners of Country throughout Australia, and their continuing connection to land, sea and community. We pay our respects to them and their cultures, and to all Elders both past and present.